Form D · Pharmaceuticals
Censa Pharmaceuticals Inc.
Cambridge, MA · CIK 0001672520
Offering snapshot reported Nov 22, 2017 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $20K Reported outside-investor minimum
- First sale
- Nov 17, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 22, 2017 | Initial | $1,500,000 | No comparison | 18 | SEC filing |
| Apr 19, 2016 | Initial | $1,505,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-299411
Source: Form D, filed Nov 22, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph Baron | Director |
| Pini Orbach | Director |
| Jonathan Reis | Director, Executive |
| Chris Schelling | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
222 Third Street, Suite 2240
Cambridge, MA, 02142
Cambridge, MA, 02142